

MEMORANDUM

TO: Honorable President and Members of the City Council
Attention: Natawna Austin, Executive Secretary

FROM: William H. Cole, President and CEO
Baltimore Development Corporation 

DATE: December 11, 2018

SUBJECT: City Council Bill No. 18-0311
Nicotine Replacement Therapy Products – Sale and Distribution

The Baltimore Development Corporation (BDC) has been asked to comment on City Council Bill No. 18-0311 for the purpose of requiring certain retailers to sell nicotine replacement therapy products; mandating certain retail display and packaging requirements; requiring certain employers and facilities to offer nicotine replacement therapy products at no cost; defining certain terms; providing for a special effective date; establishing certain penalties; and generally relating to the sale and distribution of nicotine replacement therapy products

Nicotine replacement therapy comes in different forms such as: gum, patches, nasal spray, inhaler and lozenges that assist individuals attempting to quit tobacco products. Studies have shown that nicotine replacement therapy is equally as effective as medications such as bupropion, in helping people to quit smoking for at least 6 months.

BDC has reviewed and supports the proposed legislation and is respectfully requesting that Bill No. 18-0311 be given favorable consideration by the City Council.

cc: Kyron Banks